Pain Ct-colonography Colorectal cancer Polyps
Conditions
Interventions
Subjects randomised to group 1 will receive alfentanil (Rapifen
Janssen-Cilag, Tilburg, The Netherlands) 7.5 ìg/kg intravenously through a 20 Gauge intravenous cannula. Subjects randomised to group 2 will receive a placebo, in this study a 0.9% saline solution thr
Sponsors
Academic Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: 1. 18 to 85 years; 2. Written informed consent; 3. Sceduled for CT-colonography for symptoms or increased risk for colorectal cancer.
Exclusion criteria
Exclusion criteria: 1. Hypotension (systolic pressure 4); 7. Use of MAO inhibitor or in 2 weeks before CT-colonography; 7. Use of barbiturates, opiates or daily benzodiazepine use; 8. Known increased intracranial pressure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference between the alfentanil group and placebo group in maximum pain score during insufflation. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Pain score in all insufflation positions (left and right decubitus, supine and prone) and the average pain score; 2. Pain and burden of all CT-colonography aspects (telebrix, cannula insertion, rectal catheter insertion, insufflation, turing on scanner table, post-procedure) and total pain and burden of CT-colonography; 3. Side-effects of alfentanil during CT-colonography including: A. Respiratory effects (apnoea, respiratory frequency and blood oxygenation); B. Hemodynamics (heart rate and blood pressure). 4. Procedure and recovery time; 5. The most painful and most burdenful aspect of CT-colonography. | — |
Contacts
Public ContactJ. Stoker
Academic Medical Center Radiology department Meibergdreef 9
Outcome results
None listed